About BELLEROPHON

Staphylococcus aureus, including Meticillin-resistant S. aureus (MRSA), is one of the most important bacterial pathogens, causing skin, wound, and deep infections in both the community and in hospitals. Treatment is difficult and expensive and may require prolonged intravenous antibiotic therapy. Since there is no licensed vaccine by FDA (Food and Drug Administration) or EMEA (European Medicines Agency), prevention also relies heavily on antimicrobials to which antibiotic resistance is developing. To reduce S. aureus disease burden, and antibiotic use associated with it, BELLEROPHON will design, manufacture, and assess in a phase I clinical study a novel S. aureus vaccine candidate targeting both the cellular and humoral responses. It is designed to be protective against both MRSA and more sensitive S. aureus strains.

For further information please contact us on bellerophoninfo [at] euvaccine [dot] eu.

 

Publications:

Allen et al., MRI Based Localisation and Quantification of Abscesses following Experimental S. aureus Intravenous Challenge: Application to Vaccine Evaluation. PloS One 2016 11(5):e0154705. doi: 10.1371

Das et al., Natural mutations in a Staphylococcus aureus virulence regulator attenuate cytotoxicity but permit bacteremia and abscess formation. Proc Natl Acad Sci USA 2016 113(22):E3101-10. doi: 10.1073/pnas.1520255113.

Flaxman et al., Risk factors for dermatitis in submariners during a submerged patrol: an observational cohort study. BMJ Open. 2016 ;6(6):e010975. doi: 10.1136/bmjopen-2015-010975.

Whitehouse et al., Population variation in anti-S. aureus IgG isotypes influences surface protein A mediated immune subversion.Vaccine. 201634(15):1792-9. doi: 10.1016/j.vaccine.2016.02.034.